Wei Wei Commission: Firmly Opposes Second Bargaining

“At present, we are working together with relevant departments to study and formulate a negotiation plan. This year we must select key drugs that are clinically necessary, expensive, and concerned by the society to carry out price negotiations.” On April 26, the Department of Drug Policy and Essential Drugs, Department of Health, Development and Planning Commission Sun Yang, deputy director general, stated at the Third Summit of the Chinese Medicine Industry Summit on Hot Issues: Resolutely oppose the second bargaining, and the price of medicines purchased through drug negotiations must be unified nationwide.

It is understood that the relevant ministries and commissions are working out the "Plan for the Pilot Program for the Establishment of a Drug Price Negotiation System" to propose an open and transparent multi-party price negotiation mechanism for specialized drugs and exclusive products. The price for negotiation will be used in the comprehensive information management of the national drug tender supply guarantee. The hospital purchased medicines as a result of the negotiations.

Sun Yang introduced that the drug price negotiation system is mainly aimed at patented drugs. The exclusive production of drugs has many successful negotiation experiences internationally, but for China, the previous work is basically blank. As for the way of negotiation, experts can come forward for interviews, they can also be entrusted with provincial talks, they can also talk together across regions, or they can engage in a professional field to negotiate, but this is a unified national negotiation price. At present, the Health and Weaving Commission is working with relevant departments to study and formulate a negotiation plan. In 2015, some key drugs that are clinically necessary, relatively expensive, and socially concerned should be selected for price negotiations.

Which varieties will be included in the scope of drug negotiations? Sun Yang believes that the next step is to carry out the price negotiation work. Exclusive Chinese patent medicine products will not be an exception. The exclusive varieties of chemical drugs are mostly patented drugs produced by foreign companies, and the exclusive varieties of traditional Chinese medicines are an important part of China's outstanding traditional culture. They have the characteristics of stable quality, exact curative effect, and the ability to be fixed and guaranteed. There are many Chinese patent medicines that currently have large sales volumes. Is an exclusive drug, there are more than 60 in the 2012 basic medicine list.

Sun Yang also mentioned that the elimination of medicine supplements medicine is a key link in medical reform. Breaking the medicine to make up for it must not be shaken. It must not be changed. "Some people engage in some low bargaining and higher bargaining, play with some pharmacy trusteeship, and try every means to obtain benefits from medicine. We must be firm and unshakable in this issue."